Immortelle Therapy

Immortelle Therapy is a clinical-stage biotechnology company headquartered in Shanghai, China, focused on the development of innovative cell therapies for cancer. The company specializes in chimeric antigen receptor T-cell (CAR-T) technologies, with a particular emphasis on addressing unmet needs in hematological malignancies such as multiple myeloma and B-cell lymphomas. Their pipeline includes several advanced candidates, including a GPRC5D-targeted CAR-T and a dual-targeting BCMA/GPRC5D CAR-T designed to prevent antigen escape and improve durable response rates. Immortelle Therapy utilizes proprietary manufacturing processes to enhance the quality and scalability of its autologous cell products. By targeting novel antigens and employing multi-specific constructs, the company aims to provide next-generation solutions for patients who have relapsed or are refractory to standard treatments.